Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model

International Immunopharmacology

Volumn 21, Issue 1, 2014, Pages 119-127

  Li, Qingcui ^a   Ren, Guiping ^a,b   Xu, Liming ^c   Wang, Qiuying ^a   Qi, Jianying ^a   Wang, Wenfei ^a   Zhou, Bing ^a   Han, Xiaohui ^a   Sun, Cuiyu ^a   Wu, Qiang ^a   Yu, Yinhang ^a   Peng, Zhongyi ^d   Zheng, Shimin ^a   Li, Deshan ^a,b  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^b Key Lab of Agriculture Biological Functional Gene of Heilongjiang Provincial Education Committee   (China)

^c SOUTH CHINA SEA FISHERIES RESEARCH INSTITUTE   (China)

^d Meteorological Center of Heilongjiang Province   (China)

Author keywords

Bispecific antibody; IL 17A; IL 1 ; Rheumatoid arthritis (RA)

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC ANTIBODY 1; BISPECIFIC ANTIBODY 2; BISPECIFIC ANTIBODY 3; COLLAGEN ANTIBODY; COLLAGEN TYPE 2 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; MESSENGER RNA; SODIUM CHLORIDE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; CYTOKINE; IL17A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTHRITIS; ARTICLE; BONE INJURY; CARTILAGE DEGENERATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; HL 60 CELL LINE; IN VITRO STUDY; INHIBITION KINETICS; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; ANIMAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE; CELL CULTURE; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; INBRED MOUSE STRAIN; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, BLOCKING; ANTIBODY FORMATION; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE AND BONES; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HUMANS; INTERLEUKIN-17; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED STRAINS;

EID: 84900988387     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.04.018     Document Type: Article

References (59)

1. M. Feldmann, and R.N. Maini Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19 2001 163 196 (Pubitemid 32368033)
2. J.G. Jeong, J.M. Kim, H. Cho, W. Hahn, S.S. Yu, and S. Kim Effects of IL-1beta on gene expression in human rheumatoid synovial fibroblasts Biochem Biophys Res Commun 324 2004 3 7 (Pubitemid 39311453)
3. Toru Ishibashi Molecular hydrogen: new antioxidant and anti-inflammatory therapy for rheumatoid arthritis and related diseases Curr Pharm Des 19 2013 6375 6381
4. Erik Lubberts, and I. 1 Marije Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion Arthritis Rheum 50 2004 650 659 (Pubitemid 38198849)
5. P.C. Taylor, R.O. Williams, and R.N. Maini Immunotherapy for rheumatoid arthritis Curr Opin Immunol 13 2001 611 616 (Pubitemid 32817044)
6. D.M. Lee, and M.E. Weinblatt Rheumatoid arthritis Lancet 358 2001 903 911 (Pubitemid 32900579)
7. Y. Yamanishi, and G.S. Firestein Pathogenesis of rheumatoid arthritis: the role of synoviocytes Rheum Dis Clin N Am 27 2001 355 371 (Pubitemid 32488710)
8. J.M. Dayer, U. Feige, C.K. Edwards III, and D. Burger Antiinterleukin-1 therapy in rheumatic diseases Curr Opin Rheumatol 13 2001 170 176
9. M.A. Antonysamy, W.C. Fanslow, F. Fu, W. Li, S. Qian, and A.B. Troutt et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors J Immunol 162 1999 577 584 (Pubitemid 29018969)
10. D.V. Jovanovic, J.A. Di Battista, J. Martel-Pelletier, F.C. Jolicoeur, Y. He, and M. Zhang et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1 and TNF-, by human macrophages J Immunol 160 1998 3513 3521 (Pubitemid 28164746)
11. M. Chabaud, F. Fossiez, J.L. Taupin, and P. Miossec Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines J Immunol 161 1998 409 414 (Pubitemid 28285549)
12. F. Fossiez, O. Djossou, P. Chomarat, L. Flores-Romo, S. Ait-Yahia, and C. Maat et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines J Exp Med 183 1996 2593 2603 (Pubitemid 26193037)
13. W.P. Arend, and J.-M. Dayer Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis Arthritis Rheum 38 1995 151 160
14. M. Feldmann, M.J. Elliot, J.N. Woody, and R.N. Maini Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis Adv Immunol 64 1997 283 350 (Pubitemid 27161392)
15. S. Cohen, E. Hurd, J. Cush, M. Schiff, M.E. Weinblatt, and L.W. Moreland et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebocontrolled trial Arthritis Rheum. 46 2002 614 624 (Pubitemid 34214243)
16. S. Kotake, N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, and S. Ishiyama et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis J Clin Invest 103 1999 1345 1352 (Pubitemid 29218305)
17. Zhang a Yu, and Ren a Guiping Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model Int Immunopharmacol 15 2013 199 205
18. H. Huang, and H.J. Kim IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling Cell Death Differ 16 2009 1332 1343
19. R.O.B.J. Van'T Hof, and H. Stuart Nitric oxide and bone Immunology 103 2001 255 261
20. F.H. Durie, R.A. Fava, and R.J. Noelle Collagen-induced arthritis as a model of rheumatoid arthritis Clin Immunol Immunopathol 73 1 1994 11 18 (Pubitemid 24310774)
21. Daiva Bartkeviciene, Ingrida Pilypiene, and J. Med Libyan Leukocytosis as a prognostic marker in the development of fetal inflammatory response syndrome 8 2013 10.3402/ljm.v8i0.21674
22. J.U. Scher Monotherapy in rheumatoid arthritis Bull Hosp Jt Dis 71(3 2013 204 207
23. M. Mahamid, K. Paz, M. Reuven, and R. Safadi Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports Int J Gen Med 4 2011 657 660
24. A. Molto, and A. Olive Anti-IL-1 molecules: new comers and new indications Joint Bone Spine 77 2010 102 107 [PubMed: 20045371]
25. G.J. Thorbecke, R. Shah, C.H. Leu, A.P. Kuruvilla, A.M. Hardison, and M.A. Palladino Involvement of endogenous tumor necrosis factor and transforming growth factor β during induction of collagen type II arthritis in mice Proc Natl Acad Sci U S A 89 1992 7375 7379
26. L.A.B. Joosten, M.M.A. Helsen, F.A.J. van de Loo, and W.B. van den Berg Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1 α/β, and IL-1Ra Arthritis Rheum 39 1996 797 809
27. W.B. Van den Berg, L.A. Joosten, M. Helsen, and F.A. van de Loo Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment Clin Exp Immunol 95 1994 237 243 (Pubitemid 24207133)
28. Erik Lubberts, and Marije I. Koenders Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion Arthritis Rheum 50 2 February 2004 650 659 (Pubitemid 38198849)
29. P.G. Winyard, B. Ryan, P. Eggleton, A. Nissim, E. Taylo, and M. Faro et al. Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease Biochem Soc Trans 39 2011 1226 1232
30. H. Huang, H.J. Kim, and E.-J. Chang IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling Cell Death Differ 16 2009 1332 1343
31. Hoi-Kei Lon, and Dongyang Liu Population pharmacokinetic-pharmacodynamic- disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis J Pharmacokinet Pharmacodyn 38 6 2011 December 769 786 10.1007/s10928-011-9219-z
32. K. Hadjigogos The role of free radicals in the pathogenesis of rheumatoid arthritis Panminerva Med 45 2003 7 13 (Pubitemid 38064125)
33. D.E. Evans, and S.H. Ralston Nitric oxide and bone J Bone Miner Res 11 1996 300 305 (Pubitemid 26076379)
34. I. MacIntyre, M. Zaid, A.S.M. Towhidul Alam, H.K. Datta, B.S. Moonga, and P.S. Lidbury et al. Osteoclast inhibition: an action of nitric oxide not mediated by cyclic GMP Proc Natl Acad Sci U S A 88 293& 2940 1991
35. S.H. Ralston, L.P. Ho, M. Helfrich, P.S. Grabowski, P.W. Johnston, and N. Benjamin Nitric oxide: a cytokine induced regulator of bone resorption J Bone Miner Res 1995 104 1049
36. C.W.G.M. Lowik, P.H. Nibbering, M. Van der Ruit, and S.E. Papapoulos Inducible production of nitric oxide in osteoblast like cells and in fetal bone explants is associated with suppression of osteoclastic bone resorption J Clin Invest 93 1994 1465 1472 (Pubitemid 24116382)
37. P.P. Tak, T.J.M. Smeets, M.R. Daha, P.M. Kluin, K.A.E. Meijers, and R. Brand et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity Arthritis Rheum 40 2 1997 217 225 (Pubitemid 27114085)
38. D.M. Lee, and M.E. Weinblatt Rheumatoid arthritis Lancet 358 9285 2001 903 911 (Pubitemid 32900579)
39. M. Feldmann Pathogenesis of arthritis: recent research progress Nat Immunol 2 9 2001 771 773
40. F. Fossiez, O. Djossou, P. Chomarat, L.R. Flores, S.Y. Ait, and C. Maat et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines J Exp Med 183 6 1996 2593 2603 (Pubitemid 26193037)
41. L.E. Harrington, R.D. Hatton, P.R. Mangan, H. Turner, T.L. Murphy, and K.M. Murphy et al. Interleukin 17-producing CD4 + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages Nat Immunol 6 11 2005 1123 1132 (Pubitemid 41541790)
42. L.K. Myers, E.F. Rosloniec, M.A. Cremer, and A.H. Kang Collagen induced arthritis, an animal model of autoimmunity Life Sci 61 1997 1861 1878 (Pubitemid 27461519)
43. F.H. Durie, R.A. Fava, and R.J. Noelle Collagen-induced arthritis as a model of rheumatoid arthritis Clin Immunol Immunopathol 73 1994 11 18 (Pubitemid 24310774)
44. L. Svensson, J. Jirholt, R. Holmdahl, and L. Jansson B cell-deficient mice do not develop type II collagen-induced arthritis (CIA) Clin Exp Immunol 111 1998 521 526 (Pubitemid 28160894)
45. H. Wang, O. Bloom, M. Zhang, J.M. Vishnubhakat, M. Ombrellino, and J. Che et al. HMG-1 as a late mediator of endotoxin lethality in mice Science 285 1999 nn248 nn251
46. E.H. Choy, and G.S. Panayi Cytokine pathways and joint inflammation in rheumatoid arthritis N Engl J Med 344 2001 907 916 [PubMed: 11259725] (Pubitemid 32224400)
47. C.A. Dinarello Interleukin-1 in the pathogenesis and treatment of inflammatory diseases Blood 117 2011 3720 3732 [PubMed: 21304099]
48. R.M. Fleischmann, and J. Schechtman Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial Arthritis Rheum 48 4 2003 927 934 (Pubitemid 36418234)
49. M.H. Schiff Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis Ann Rheum Dis 59 Suppl. 1 2000 i103 i108
50. E. Lee, W.L. Trepicchio, J.L. Oestreicher, D. Pittman, F. Wang, and F. Chamian et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris J Exp Med 199 2004 125 130 (Pubitemid 38076484)
51. G. Piskin, R.M.R. Sylva-Steenland, J.D. Bos, and M.B.M. Teunissen In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin J Immunol 176 2006 1908 1915 (Pubitemid 43134336)
52. U. Muller-Ladner, T. Pap, R.E. Gay, M. Neidhart, and S. Gay Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis Nat Clin Pract Rheumatol 1 2 2005 102 110
53. J.M. Dayer, U. Feige, C.K. Edwards III, and D. Burger Anti-interleukin-1 therapy in rheumatic diseases Curr Opin Rheumatol 13 2001 170 176 (Pubitemid 32430067)
54. M. Feldmann, F.M. Brennan, and R.N. Maini Role of cytokines in rheumatoid arthritis Annu Rev Immunol 14 1996 397 440 (Pubitemid 26130190)
55. K. Asadullah, W. Sterry, and H.D. Volk Interleukin-10 therapy - review of a new approach Pharmacol Rev 55 2003 241 269 (Pubitemid 36666048)
56. V.R. Juárez-González, and L. Riaño-Umbarila Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2 J Mol Biol 346 5 Mar 11 2005 1287 1297 [Epub 2005 Jan 16] (Pubitemid 40248829)
57. L. Du, L.J. Zhou, X.J. Pan, Y.X. Wang, Q.Z. Xu, and Z.H. Yang et al. Radiosensitization and growth inhibition of cancer cells mediated by an scFv antibody gene against DNA-PKcs in vitro and in vivo Radiat Oncol 5 2010 70
58. V. Quintero-Hernández, and VR Juárez-González The change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies Mol Immunol 44 2007 Feb 1307 1315 [Epub 2006 Jun 30] (Pubitemid 44415962)
59. Jianying Qi, and Xianlong Ye Pharmacological efficacy of anti-IL-1β scFv. Fab and full-length antibodies in treatment of rheumatoid arthritis Mol Immunol 57 2 February 2014 59 65